GRACEcast
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Visit Show Website http://cancerGRACE.org/Recently Aired
-
HD
ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (audio)
Dr. David Gerber, University of Texas-Southwestern, reviews the results of ...
Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.
-
HD
ASCO Lung Cancer Highlights, Part 5: Updates in Maintenance Therapy for Advanced NSCLC (video)
Dr. David Gerber, University of Texas-Southwestern, discusses results of two ...
Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the PRONOUNCE trial and POINTBREAK trials.
-
HD
ASCO Lung Cancer Highlights, Part 5: Updates in Maintenance Therapy for Advanced NSCLC (audio)
Dr. David Gerber, University of Texas-Southwestern, discusses results of two ...
Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the PRONOUNCE trial and POINTBREAK trials.
-
HD
Dr. Rosalyn Juergens: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Rosalyn Juergens, McMaster University, provides her perspective on the ...
Dr. Rosalyn Juergens, McMaster University, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other LC subtypes.
-
HD
Dr. Greg Riely on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Dr. Greg Riely, from Memorial Sloan-Kettering, describes which patients with ...
Dr. Greg Riely, from Memorial Sloan-Kettering, describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.
-
HD
Chemotherapy for Pancreatic Cancer, Part 1: Background and Molecular Biology (video)
Dr. Colin Weekes, pancreatic cancer specialist from the University of ...
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the role of chemotherapy in pancreatic cancer, beginning with the molecular biology of pancreatic cancer.
-
HD
Chemotherapy for Pancreatic Cancer, Part 1: Background and Molecular Biology (audio)
Dr. Colin Weekes, pancreatic cancer specialist from the University of ...
Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the role of chemotherapy in pancreatic cancer, beginning with the molecular biology of pancreatic cancer.
-
HD
ASCO Lung Cancer Highlights, Part 4: Exploring the Role of Trimodality Therapy for Stage III NSCLC (video)
Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study ...
Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.
-
HD
ASCO Lung Cancer Highlights, Part 4: Exploring the Role of Trimodality Therapy for Stage III NSCLC (audio)
Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study ...
Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.
-
HD
ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (video)
Dr. David Gerber, University of Texas-Southwestern, reviews results of the ...
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
